Floatz logo

Capivasertib

Metastatic Breast Cancer

Maryam LustbergSmall moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
73/ 100

Competitive context

61 Active assets in the Metastatic Breast Cancer cohort.

Asset / SponsorPhaseRating
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
Alisertib
Puma Biotechnology, Inc.
Phase 2BB
Bp-C1
Meabco A/S
Phase 2BB
Trastuzumab Emtansine
Genentech, Inc.
Phase 2BB
Encequidar
Health Hope Pharma
Phase 3B

View all 50 →

Same molecule, other indications

Capivasertib is also rated in:

triple-negative breast carcinomaDormant
BB
Indicative ·
71 / 100
View asset →
estrogen-receptor positive breast cancerDormant
BB
Indicative ·
70 / 100
View asset →
Advanced Non-small-cell Lung CancerDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →